一名免疫功能正常、伴有MYC和BCL6重排（双打击淋巴瘤）的坏死性原发性中枢神经系统淋巴瘤患者：病例报告
A necrotic primary central nervous system lymphoma in immunocompetent patient with MYC and BCL6 rearrangements (double-hit lymphoma): a case report.
作者信息
Khalil Nabil C N, Iwaiwi Bashaer Imad, Hammad Shurooq, Jobran Afnan W M, Itkaidek Saeed, Lahham Elias Edward
机构信息
Research Department, Faculty of Medicine, Al-Quds University, Jerusalem, Palestine.
Department of Neurosurgery, Al-Ahli Hospital, Hebron, Palestine.
出版信息
Oxf Med Case Reports. 2023 Mar 25;2023(3):omad026. doi: 10.1093/omcr/omad026. eCollection 2023 Mar.
Abstract
Primary Central Nervous System Lymphoma (PCNSL) is a rare, aggressive extranodal non-Hodgkin lymphoma. It is critical to get a diagnosis and start therapy as soon as possible to improve clinical results. Despite a new medicinal strategy that has increased survivability, the survival rate is still quite low. This report presents a new case of PCNSL that appears in an immunocompetent patient with two different rare genetic rearrangements and a necrotic histological appearance.
摘要
原发性中枢神经系统淋巴瘤（PCNSL）是一种罕见的、侵袭性结外非霍奇金淋巴瘤。尽快进行诊断并开始治疗对于改善临床结果至关重要。尽管新的药物策略提高了生存率，但存活率仍然很低。本报告介绍了一例发生在免疫功能正常患者身上的PCNSL新病例，该患者有两种不同的罕见基因重排且组织学表现为坏死。
相似文献
1
A necrotic primary central nervous system lymphoma in immunocompetent patient with MYC and BCL6 rearrangements (double-hit lymphoma): a case report.
Oxf Med Case Reports. 2023 Mar 25;2023(3):omad026. doi: 10.1093/omcr/omad026. eCollection 2023 Mar.
2
Analysis of primary central nervous system large B-cell lymphoma in the era of high-grade B-cell lymphoma: Detection of two cases with MYC and BCL6 rearrangements in a cohort of 12 cases.
Ann Diagn Pathol. 2020 Oct;48:151610. doi: 10.1016/j.anndiagpath.2020.151610. Epub 2020 Aug 25.
3
MYC, BCL2, and BCL6 rearrangements in primary central nervous system lymphoma of large B cell type.
Ann Hematol. 2019 Jan;98(1):169-173. doi: 10.1007/s00277-018-3498-z. Epub 2018 Oct 11.
4
Double-hit and double-expressor primary central nervous system lymphoma: Experience from North India of an infrequent but aggressive variant.
Surg Neurol Int. 2023 May 12;14:172. doi: 10.25259/SNI_307_2023. eCollection 2023.
5
Double-hit primary central nervous system lymphoma with histogenetically proven bone marrow infiltration: a case report and a review of the literature.
Brain Tumor Pathol. 2024 Oct;41(3-4):145-150. doi: 10.1007/s10014-024-00490-z. Epub 2024 Aug 31.
6
Impact of oncogene rearrangement patterns on outcomes in patients with double-hit non-Hodgkin lymphoma.
Cancer. 2016 Feb 15;122(4):559-64. doi: 10.1002/cncr.29781. Epub 2015 Nov 13.
7
Correction to: A necrotic primary central nervous system lymphoma in immunocompetent patient with MYC and BCL6 rearrangements (double-hit lymphoma): a case report.
Oxf Med Case Reports. 2023 Jun 26;2023(6):omad069. doi: 10.1093/omcr/omad069. eCollection 2023 Jun.
8
Clinicopathological and genomic analysis of double-hit follicular lymphoma: comparison with high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements.
Mod Pathol. 2018 Feb;31(2):313-326. doi: 10.1038/modpathol.2017.134. Epub 2017 Oct 6.
9
Del(6)(q22) and BCL6 rearrangements in primary CNS lymphoma are indicators of an aggressive clinical course.
J Clin Oncol. 2008 Oct 10;26(29):4814-9. doi: 10.1200/JCO.2008.16.1455. Epub 2008 Jul 21.
10
Primary Central Nervous System Lymphoma in an Immunocompetent Young Adult Patient: A Rare Case.
Acta Med Indones. 2023 Jan;55(1):107-109.
本文引用的文献
1
Primary Central Nervous System Lymphomas: A Diagnostic Overview of Key Histomorphologic, Immunophenotypic, and Genetic Features.
Diagnostics (Basel). 2020 Dec 11;10(12):1076. doi: 10.3390/diagnostics10121076.
2
Reduced-dose whole-brain radiotherapy with tumor bed boost after upfront high-dose methotrexate for primary central nervous system lymphoma.
Radiat Oncol J. 2020 Mar;38(1):35-43. doi: 10.3857/roj.2020.00052. Epub 2020 Mar 25.
3
Surgical Resection for Primary Central Nervous System Lymphoma: A Systematic Review.
World Neurosurg. 2019 Jun;126:e1436-e1448. doi: 10.1016/j.wneu.2019.02.252. Epub 2019 Mar 20.
4
Comprehensive approach to diagnosis and treatment of newly diagnosed primary CNS lymphoma.
Neuro Oncol. 2019 Feb 19;21(3):296-305. doi: 10.1093/neuonc/noy192.
5
Challenges and opportunities in primary CNS lymphoma: A systematic review.
Radiother Oncol. 2017 Mar;122(3):352-361. doi: 10.1016/j.radonc.2016.12.033. Epub 2017 Jan 16.
6
Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial.
Lancet Haematol. 2016 May;3(5):e217-27. doi: 10.1016/S2352-3026(16)00036-3. Epub 2016 Apr 6.
7
The 2016 revision of the World Health Organization classification of lymphoid neoplasms.
Blood. 2016 May 19;127(20):2375-90. doi: 10.1182/blood-2016-01-643569. Epub 2016 Mar 15.
8
Diffuse large B-cell lymphoma with MYC gene rearrangements: Current perspective on treatment of diffuse large B-cell lymphoma with MYC gene rearrangements; case series and review of the literature.
Eur J Cancer. 2016 Mar;55:140-6. doi: 10.1016/j.ejca.2015.12.001. Epub 2016 Jan 25.
9
Diagnosis and treatment of primary CNS lymphoma.
Nat Rev Neurol. 2013 Jun;9(6):317-27. doi: 10.1038/nrneurol.2013.83. Epub 2013 May 14.
Zotero 插件